We have recently demonstrated that in advanced melanoma, patients with low expression of MHC-I on the surface of tumor cells, were unlikely to benefit from anti-PD-1 monotherapy but could still respond to the combined treatment (anti-PD-1 and anti-CTLA-4) [34]. This evidence concerns the gene CTLA4 and neoplasm.